Overview
Tal Kan practices practicing medicine in Haifa, Israel.
His clinical expertise encompasses Lung Cancer, Mesothelioma, Pancreatic Ductal Adenocarcinoma, and Glioblastoma.
He is actively involved in clinical research, co-authoring 11 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Tal Kan
Is Tal Kan a top-rated expert for Lung Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Tal Kan is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Tal Kan participate in research or clinical trials?
Yes. Tal Kan has published 11 articles and abstracts on conditions like Lung Cancer. You can view a list of Tal Kan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- AstrocytomaMr. Kan isExperienced. Learn about Astrocytoma.
- GlioblastomaMr. Kan isExperienced. Learn about Glioblastoma.
- Lung CancerMr. Kan isExperienced. Learn about Lung Cancer.
- MesotheliomaMr. Kan isExperienced. Learn about Mesothelioma.
- Pancreatic Ductal AdenocarcinomaMr. Kan isExperienced. Learn about Pancreatic Ductal Adenocarcinoma.